Wanting to invest in the healthcare sector in FY 2026? If you are, then it could be worth checking out the ASX healthcare shares in this article.
That's because analysts at Bell Potter have named them as best buys for the year ahead. Let's see what the broker is recommending:
Monash IVF Group Ltd (ASX: MVF)
The first ASX healthcare share that could be a top buy is fertility treatment company Monash IVF.
Bell Potter highlights that the company's shares have been sold off recently due to embryo transfer errors. It feels that the selling has been overdone and created a buying opportunity for investors. It explains:
The share price has more than halved over the past six months in light of recent episodes of embryo transfer errors, resulting in the resignation of the CEO. We consider the negative share price reaction to be excessive, and with MVF trading at c.6x on an EV/ EBITDA basis, the valuation metrics look compelling, when compared with the buyout of Virtus Health at c.12.5x. The depressed share price may also invite a bid for the company adding corporate appeal to a deep value investment thesis.
Bell Potter has a buy rating and $1.15 price target on its shares.
Neuren Pharmaceuticals Ltd (ASX: NEU)
Another ASX healthcare share that could be a buy is drug development company Neuren Pharmaceuticals.
The broker likes the company due to the royalty stream from its Daybue product and its promising NNZ-2591 product, which is under development. It said:
With A$341m cash and no debt as of 31-March-2025, we remain confident NEU will be able to fund multiple Phase 3 trials and recruit the 160 subjects for the first Phase 3 trial relatively smoothly. We view NNZ-2591 as the key value driver for NEU and remain optimistic about its prospects for success following promising Phase 2 data. As the Phase 3 trial proceeds through recruitment across CY25-26, we expect the share price to further appreciate as the readout draws nearer.
It has a buy rating and $20.00 price target on Neuren Pharmaceuticals' shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
A third ASX healthcare share that could be a best buy in FY 2026 is Telix Pharmaceuticals.
It is a leading radiopharmaceuticals company developing products for the imaging and treatment of solid tumours.
Bell Potter believes it is well-placed for growth thanks to the popularity of Illuccix and the recent approval of Gozellix. It said:
The lead product is Illuccix, where revenues continue to grow as the market for PSMA PET expands and as the company takes share in its key market in the United States. We expect average selling price will largely be preserved as the company switches most of its Medicare outpatient client base to the recently approved Gozellix format from 1 October 2025 when the refresh on the pass through pricing is expected to come to bear.
Elsewhere, we anticipate the approval of Zircaix in 3Q25 for the imaging of clear cell renal cell carcinoma (ccRCC). Additional short term catalysts include interim data from the PROSTACT Global trial regarding safety and dosimetry from the 30 patient run in study.
Bell Potter has a buy rating and $34.00 price target on its shares.
